anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Image

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 119,566
Current window 88,201-88,230
Pages 3,986
Rows per page 30
Component: Imageclear collectionreset all
18 30 60

Component

88,201-88,230 of 119,566

filter-aware
07
The slide uses a horizontal timeline to track progress against specific technical and production milestones.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Early Struggles1 hit
08
The slide uses a funnel-like progression for the pipeline and highlights specific customer logos under the 'Contracted Fleets' stage.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
11
Uses a map-based layout to associate product types with regional progress.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
12
The slide uses icons to categorize milestones into Organization, Fuel cell, and Vehicle.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
15
The table includes both GAAP financial metrics and supplemental non-GAAP/operational data.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and therapy type (CAR-T vs TSTx).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
13
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and page number 26 bottom-right.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
Includes a process diagram showing the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
28
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor growth.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
29
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The slide uses a process-flow style layout to connect platform capabilities to specific drug candidates.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide uses a '3 Pillars' framework to explain the platform's foundation, leading into specific product applications.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
Includes technical diagrams of the drug structure, bar charts for expression, and a Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Includes multiple scientific diagrams and clinical trial data summaries.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Selected Nexcella Scientific Advisory Board Members (bottom).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
45
The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs ($33.4bn vs $0.9bn).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo, likely to frame the market opportunity for IMX-120.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
06
The slide explicitly notes that these are cross-trial comparisons and not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
09
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a cartoon liver character at the bottom.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
17
Includes comparative charts for transduction efficiency and anti-exhaustion capability.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit